Zhu Cheng-Ying, Yang Hua, Niu Jian-Hua, Zhang Qi, Zhu Hai-Yan, Yao Zi-Long, Yu Li, Jing Yu
Department of Hematology, Chinese PLA General Hospital, Beijing 1000853, China.
Department of Hematology and Oncology, The Jinan Forth People's Hospital, Jinan 250031, Shandong Province, China.
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014 Apr;22(2):425-8. doi: 10.7534/j.issn.1009-2137.2014.02.029.
This study was purposed to analyze the clinical feature,diagnosis and treatment efficacy of primary granulocytic sarcoma (PGS). A total of 15 patients with PGS from January 2008 to March 2013 was evaluated retrospectively, among 15 patients 8 patients were treated with chemotherapy (chemotherapy alone,chemotherapy combined with local irradiation,chemotherapy combined with surgical resection or bone marrow transplantation), 7 patients were treated without chemotherapy, but were treated with surgical resection or surgical resection plus local irradiation.The chemotherapy method for PGS patients was similar as treatment of acute myeloid leukemia. The results indicated that the proportion of disease progression into bone marrow abnormality in patients treated with chemotherapy and in patients treated without chemotherapy was 25% and 85.7% respectively, suggesting that the chemotherapy can reduce the incidence of progression into bone marrow abnormality (P < 0.05). The average survival time of PGS patients treated with chemotherapy or without chemotherapy was 26.063 ± 14.97 and 12.214 ± 6.83 months (P < 0.05),suggesting prolonging of survival time of patients treated with chemotherapy, moreover 2 patients who were treated using chemotherapy combined with bone marrow transplantation still alive now,and their living times were 39 months and 45 months respectively. It is concluded that intensive chemotherapy similar as treatment of AML can decrease the probability of disease progressing into bone marrow abnormality, and if chemotherapy combines with bone marrow transplantation, the survival time of PGS patients can be longer. In this aspect, the efficacy of treatment and survival time at home and abroad are similar.
本研究旨在分析原发性粒细胞肉瘤（PGS）的临床特征、诊断及治疗效果。回顾性评估了2008年1月至2013年3月期间共15例PGS患者，其中8例患者接受了化疗（单纯化疗、化疗联合局部放疗、化疗联合手术切除或骨髓移植），7例患者未接受化疗，而是接受了手术切除或手术切除加局部放疗。PGS患者的化疗方法与急性髓系白血病的治疗相似。结果表明，接受化疗的患者和未接受化疗的患者疾病进展为骨髓异常的比例分别为25%和85.7%，提示化疗可降低进展为骨髓异常的发生率（P<0.05）。接受化疗或未接受化疗的PGS患者的平均生存时间分别为26.063±14.97个月和12.214±6.83个月（P<0.05），提示化疗可延长患者的生存时间，此外，2例接受化疗联合骨髓移植治疗的患者目前仍存活，其生存时间分别为39个月和45个月。结论是，与AML治疗相似的强化化疗可降低疾病进展为骨髓异常的概率，且化疗联合骨髓移植可使PGS患者的生存时间更长。在这方面，国内外的治疗效果和生存时间相似。
